http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9938272-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1f78cc9f3957f36776a10e0bbe93042d |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-14 |
| filingDate | 2015-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c2ea21ba4ff2e5704160188c3d6e5ee4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d7b6678ecb342b134da3f1010a340bbf http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_301a8bba927fd66e1621d1cf6a12b92b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7c2bb5b9736112eab10251ccb16f2d95 |
| publicationDate | 2018-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-9938272-B2 |
| titleOfInvention | Hydrazine compound as blood coagulation factor Xa inhibitor |
| abstract | Provided is a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X is selected from a 3-9 membered carbon ring or a ring which is formed by 3-9 membered carbocyclic ring fused with benzo ring, and a 4-10 membered heterocyclic ring or a ring which is formed by 4-10 membered heterocyclic ring fused with benzo ring; Y and Z are independently selected from 4-9 membered saturated heterocyclic rings respectively; R 1-3 are independently selected from H, F, Cl, Br, I, CN, OH, SH, NH 2 , CHO, COOH respectively, or selected from the group, optionally substituted by R 01 , consisting of C 1-10 alkyl, C 1-10 heteroalkyl, C 3-10 cyclohydrocarbyl, C 3-10 heterocyclohydrocarbyl, C 1-10 alkyl substituted by C 3-10 cyclohydrocarbyl or C 3-10 heterocyclohydrocarbyl, and C 1-10 heteroalkyl substituted by C 3-10 cyclohydrocarbyl or C 3-10 heterocyclohydrocarbyl. The compound can be used as an anticoagulant for treating and preventing thrombotic disorders, and can meet the real needs of selectivity and a potent inhibitor for coagulation Xa. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11247987-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11535618-B2 |
| priorityDate | 2014-05-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1293.